GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | LEP | multiple interactions | EXP | | 6480464 | CTD | 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of LEP mRNA]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of LEP mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LEP mRNA; [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Rosiglitazone] results in increased expression of LEP mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of LEP mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LEP mRNA; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LEP mRNA; Dichlorodiphenyl Dichloroethylene promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of LEP mRNA]; T 0070907 inhibits the reaction [[Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LEP mRNA]; T 0070907 inhibits the reaction [[triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with INS protein] results in increased expression of LEP mRNA] | PMID:19186324 PMID:23086663 PMID:26200599 PMID:28628672 PMID:31596606 | LEP | multiple interactions | ISO | Lep (Mus musculus) | 6480464 | CTD | [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased secretion of LEP protein; [licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of LEP mRNA; [Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of LEP mRNA; [Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased secretion of LEP protein; [Rosiglitazone affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in decreased expression of LEP mRNA; [Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LEP mRNA; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of LEP mRNA; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased secretion of LEP protein; [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of and results in decreased secretion of LEP protein; [sodium arsenite co-treated with Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of LEP mRNA; [triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LEP mRNA; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; Plant Extracts inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased secretion of LEP protein]; sodium arsenite promotes the reaction [[Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of LEP mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; T 0070907 inhibits the reaction [[Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LEP mRNA]; T 0070907 inhibits the reaction [[triflumizol co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of LEP mRNA] | PMID:23086663 PMID:27163856 PMID:28285642 PMID:29288687 PMID:34968464 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |